Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases

Trial Profile

Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Treosulfan (Primary) ; Busulfan
  • Indications Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders
  • Focus Therapeutic Use
  • Sponsors Medac
  • Most Recent Events

    • 11 Jul 2017 The trial has been completed in Austria.
    • 05 Apr 2017 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
    • 05 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top